Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ZAI LAB LIMITED

(ZLAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK« (tisotumab vedotin-tftv)

09/27/2022 | 08:00am EST

Seagen Inc. and Zai Lab Limited announced an exclusive collaboration and license agreement for the development and commercialization of TIVDAK® (tisotumab vedotin-tftv) in mainland China, Hong Kong, Macau, and Taiwan. TIVDAK is the first and only ADC approved in the U.S. for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Under the terms of the agreement, Seagen will receive an upfront payment of $30 million, as well as development, regulatory, and commercial milestone payments, and tiered royalties on net sales of TIVDAK in the Zai Lab territory.

Based on the existing TIVDAK co-development and co-commercialization collaboration between Seagen and Genmab, all upfront, milestone payments, and royalties will be shared 50/50 with Genmab. In 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval for TIVDAK for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. As verification and description of clinical benefit in the U.S., and to support further global regulatory applications, a confirmatory phase 3 open-label, randomized, global clinical trial, innovaTV 301, is ongoing.


ę S&P Capital IQ 2022
Stocks mentioned in the article
ChangeLast1st jan.
SEAGEN INC. 1.23% 119.36 Delayed Quote.-22.79%
ZAI LAB LIMITED -2.97% 32.99 Delayed Quote.-47.51%
All news about ZAI LAB LIMITED
12/05Zai Lab Partner Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurren..
GL
12/05Zai Lab Partner Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurren..
AQ
12/05Asian Equities Decline Despite Reports China Will Further Ease COVID Restrictions
MT
11/30Zai Lab : to Present Interim Overall Survival Results for ZEJULA« (niraparib) from the Pha..
PU
11/29Hopes of Easing COVID Restrictions Boost Asian Equities
MT
11/18JPMorgan Chase Lowers Price Target on Zai Lab to $79 From $96, Maintains Overweight Rat..
MT
11/17Asian Equities Diverge From US Markets, Climb in Thursday Trading
MT
11/15Zai Lab Grants American Depositary Shares
MT
11/11Asian ADRs Surge Higher in Friday Trading as China Eases COVID-19 Restrictions
MT
11/11Citigroup Adjusts Price Target on Zai Lab to $127 From $199, Maintains Buy Rating
MT
More news
Analyst Recommendations on ZAI LAB LIMITED
More recommendations
Financials (USD)
Sales 2022 215 M - -
Net income 2022 -464 M - -
Net cash 2022 967 M - -
P/E ratio 2022 -6,33x
Yield 2022 -
Capitalization 3 166 M 3 166 M -
EV / Sales 2022 10,2x
EV / Sales 2023 5,47x
Nbr of Employees 1 951
Free-Float 97,4%
Chart ZAI LAB LIMITED
Duration : Period :
Zai Lab Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZAI LAB LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 32,99 $
Average target price 82,53 $
Spread / Average Target 150%
EPS Revisions
Managers and Directors
Ying Du Chairman & Chief Executive Officer
Billy Cho Chief Financial Officer
Ning Xu Executive VP & Head-Clinical Operations
James Yan Chief Operating Officer-Research & Development
Peter Huang Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
ZAI LAB LIMITED-47.51%3 263
CSL LIMITED3.46%97 405
SAMSUNG BIOLOGICS CO.,LTD.-7.97%45 203
BIOGEN INC.22.02%41 972
WUXI BIOLOGICS (CAYMAN) INC.-42.63%28 815
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-31.58%19 611